Cargando…
Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors
The Severe Acute Respiratory Syndrome (SARS) is a serious life-threatening and strikingly mortal respiratory illness caused by SARS-CoV. SARS-CoV which contains a chymotrypsin-like main protease analogous to that of the main picornavirus protease, 3CL(pro). 3CL(pro) plays a pivotal role in the viral...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111328/ https://www.ncbi.nlm.nih.gov/pubmed/24316352 http://dx.doi.org/10.1016/j.bmc.2013.11.028 |
_version_ | 1783513266276794368 |
---|---|
author | Liu, Wei Zhu, He-Min Niu, Guo-Jun Shi, En-Zhi Chen, Jie Sun, Bo Chen, Wei-Qiang Zhou, Hong-Gang Yang, Cheng |
author_facet | Liu, Wei Zhu, He-Min Niu, Guo-Jun Shi, En-Zhi Chen, Jie Sun, Bo Chen, Wei-Qiang Zhou, Hong-Gang Yang, Cheng |
author_sort | Liu, Wei |
collection | PubMed |
description | The Severe Acute Respiratory Syndrome (SARS) is a serious life-threatening and strikingly mortal respiratory illness caused by SARS-CoV. SARS-CoV which contains a chymotrypsin-like main protease analogous to that of the main picornavirus protease, 3CL(pro). 3CL(pro) plays a pivotal role in the viral replication cycle and is a potential target for SARS inhibitor development. A series of isatin derivatives as possible SARS-CoV 3CL(pro) inhibitors was designed, synthesized, and evaluated by in vitro protease assay using fluorogenic substrate peptide, in which several showed potent inhibition against the 3CL(pro). Structure–activity relationship was analyzed, and possible binding interaction modes were proposed by molecular docking studies. Among all compounds, 8k(1) showed most potent inhibitory activity against 3CL(pro) (IC(50) = 1.04 μM). These results indicated that these inhibitors could be potentially developed into anti-SARS drugs. |
format | Online Article Text |
id | pubmed-7111328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71113282020-04-02 Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors Liu, Wei Zhu, He-Min Niu, Guo-Jun Shi, En-Zhi Chen, Jie Sun, Bo Chen, Wei-Qiang Zhou, Hong-Gang Yang, Cheng Bioorg Med Chem Article The Severe Acute Respiratory Syndrome (SARS) is a serious life-threatening and strikingly mortal respiratory illness caused by SARS-CoV. SARS-CoV which contains a chymotrypsin-like main protease analogous to that of the main picornavirus protease, 3CL(pro). 3CL(pro) plays a pivotal role in the viral replication cycle and is a potential target for SARS inhibitor development. A series of isatin derivatives as possible SARS-CoV 3CL(pro) inhibitors was designed, synthesized, and evaluated by in vitro protease assay using fluorogenic substrate peptide, in which several showed potent inhibition against the 3CL(pro). Structure–activity relationship was analyzed, and possible binding interaction modes were proposed by molecular docking studies. Among all compounds, 8k(1) showed most potent inhibitory activity against 3CL(pro) (IC(50) = 1.04 μM). These results indicated that these inhibitors could be potentially developed into anti-SARS drugs. Elsevier Ltd. 2014-01-01 2013-11-21 /pmc/articles/PMC7111328/ /pubmed/24316352 http://dx.doi.org/10.1016/j.bmc.2013.11.028 Text en Copyright © 2013 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Liu, Wei Zhu, He-Min Niu, Guo-Jun Shi, En-Zhi Chen, Jie Sun, Bo Chen, Wei-Qiang Zhou, Hong-Gang Yang, Cheng Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors |
title | Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors |
title_full | Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors |
title_fullStr | Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors |
title_full_unstemmed | Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors |
title_short | Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors |
title_sort | synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as sars-cov 3c-like protease inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111328/ https://www.ncbi.nlm.nih.gov/pubmed/24316352 http://dx.doi.org/10.1016/j.bmc.2013.11.028 |
work_keys_str_mv | AT liuwei synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors AT zhuhemin synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors AT niuguojun synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors AT shienzhi synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors AT chenjie synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors AT sunbo synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors AT chenweiqiang synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors AT zhouhonggang synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors AT yangcheng synthesismodificationanddockingstudiesof5sulfonylisatinderivativesassarscov3clikeproteaseinhibitors |